Mayer Brown advises SERB Pharmaceuticals and its majority shareholder Charterhouse Capital Partners on the structuring of the acquisition of RSDL® (Reactive Skin Decontamination Lotion)

Advising firms

The announcement does not name individual lawyers.

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value

Not stated

What the figure measures

Not stated

Client

SERB Pharmaceuticals and its majority shareholder Charterhouse Capital PartnersBuy-side

Counterparties

Emergent BioSolutions Inc. (Sell-side)